AngioDynamics, Inc. (NASDAQ:ANGO) Shares Sold by Franklin Resources Inc.

Franklin Resources Inc. cut its stake in AngioDynamics, Inc. (NASDAQ:ANGO) by 2.4% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 61,784 shares of the medical instruments supplier’s stock after selling 1,502 shares during the quarter. Franklin Resources Inc. owned approximately 0.15% of AngioDynamics worth $481,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of ANGO. Segall Bryant & Hamill LLC increased its holdings in AngioDynamics by 142.7% in the third quarter. Segall Bryant & Hamill LLC now owns 911,443 shares of the medical instruments supplier’s stock valued at $7,091,000 after buying an additional 535,958 shares in the last quarter. Millennium Management LLC increased its stake in shares of AngioDynamics by 41.9% in the 2nd quarter. Millennium Management LLC now owns 1,793,454 shares of the medical instruments supplier’s stock valued at $10,850,000 after purchasing an additional 529,861 shares in the last quarter. Systematic Financial Management LP raised its holdings in AngioDynamics by 14.3% in the 3rd quarter. Systematic Financial Management LP now owns 2,410,346 shares of the medical instruments supplier’s stock worth $18,752,000 after purchasing an additional 300,785 shares during the period. First Eagle Investment Management LLC purchased a new position in AngioDynamics during the second quarter worth approximately $1,321,000. Finally, Royce & Associates LP grew its holdings in AngioDynamics by 10.8% in the third quarter. Royce & Associates LP now owns 986,073 shares of the medical instruments supplier’s stock valued at $7,672,000 after purchasing an additional 96,138 shares during the period. Hedge funds and other institutional investors own 89.43% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of AngioDynamics in a research report on Tuesday, December 10th. Canaccord Genuity Group decreased their price target on shares of AngioDynamics from $13.00 to $12.00 and set a “buy” rating on the stock in a research note on Friday, October 4th.

Insider Transactions at AngioDynamics

In other news, CEO James C. Clemmer purchased 20,000 shares of the company’s stock in a transaction dated Monday, October 7th. The stock was acquired at an average price of $6.03 per share, with a total value of $120,600.00. Following the purchase, the chief executive officer now directly owns 681,582 shares in the company, valued at approximately $4,109,939.46. This represents a 3.02 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Insiders have purchased a total of 22,568 shares of company stock worth $135,847 in the last quarter. Company insiders own 5.40% of the company’s stock.

AngioDynamics Stock Up 1.6 %

Shares of NASDAQ ANGO opened at $9.05 on Tuesday. The firm has a 50-day simple moving average of $7.61 and a 200-day simple moving average of $7.16. The stock has a market capitalization of $367.74 million, a price-to-earnings ratio of -1.49 and a beta of 0.68. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $9.58.

AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, October 3rd. The medical instruments supplier reported ($0.11) EPS for the quarter, beating analysts’ consensus estimates of ($0.15) by $0.04. The company had revenue of $67.50 million during the quarter, compared to the consensus estimate of $67.93 million. AngioDynamics had a negative net margin of 83.95% and a negative return on equity of 5.86%. AngioDynamics’s quarterly revenue was down 14.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.12) EPS. As a group, equities research analysts expect that AngioDynamics, Inc. will post -0.41 EPS for the current year.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.